The FDA cleared RHA Dynamic Volume for midface augmentation and age-related volume loss, broadening Revance's dynamic-filler portfolio beyond the original RHA Collection indication for facial lines. Dynamic fillers — which retain movement and adapt to facial expression — have gained clinical traction as practitioners move away from overfilled, static results. RHA's mechanism (reverse crosslinking) is distinct from traditional HA fillers and appeals to patients seeking natural-looking correction.
Injectables
FDA Clears RHA Dynamic Volume for Midface Augmentation — Revance's Dynamic Filler Gains Broader Indication
Revance's RHA line now covers midface volume loss; the approval expands the dynamic-filler category beyond facial lines.

1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |